Case Overview: A class action lawsuit alleges that Hims & Hers falsely advertised its compounded semaglutide GLP-1 products as equivalent to FDA-approved weight loss drugs Ozempic and Wegovy.

Consumers Affected: Individuals who purchased compounded semaglutide GLP-1 products from Hims & Hers

Court: Not yet confirmed

Hims & Hers Hit With Class Action Over Allegedly False Semaglutide Advertising

A new class action lawsuit alleges that telehealth company Hims & Hers misled consumers by marketing its compounded semaglutide products as equivalent to the blockbuster prescription drugs Ozempic and Wegovy — brand-name medications that have dominated headlines for their use in diabetes management and weight loss.

According to a recent report on the class action filing, the lawsuit claims that Hims & Hers promoted its compounded GLP-1 semaglutide offerings in ways that allegedly led customers to believe they were receiving the same product as the FDA-approved name-brand injections — when, the complaint contends, they were not.

Lawsuit Claims Products Were Misrepresented to Consumers

At the heart of the case is an allegation of false advertising. The complaint claims that Hims & Hers positioned its compounded semaglutide as a bioequivalent or identical alternative to Ozempic and Wegovy, two drugs manufactured by Novo Nordisk that have received FDA approval for specific medical indications.

The lawsuit alleges that this marketing was misleading because compounded drugs — medications mixed or altered by a compounding pharmacy — are not FDA-approved and have not undergone the same rigorous clinical testing as their brand-name counterparts. According to the complaint, consumers who purchased these products did so based on the belief that they were getting the same therapeutic benefit as the name-brand drugs, a belief the lawsuit contends Hims & Hers actively cultivated.

The plaintiff claims that had they known the compounded product was not equivalent to FDA-approved semaglutide, they would not have made the purchase — or would have paid significantly less for it.

What Is Compounded Semaglutide?

Semaglutide is the active ingredient in both Ozempic, approved for type 2 diabetes management, and Wegovy, approved for chronic weight management. Both drugs belong to a class of medications known as GLP-1 receptor agonists, which work by mimicking a hormone that regulates blood sugar and appetite.

During a period of sustained nationwide shortages of Ozempic and Wegovy, the FDA permitted compounding pharmacies to produce copies of semaglutide to help meet patient demand. Hims & Hers was among the telehealth and pharmacy companies that moved into this space, offering compounded semaglutide subscriptions to consumers seeking access to GLP-1 therapy.

However, the FDA has consistently noted that compounded drugs are not FDA-approved and that their safety, efficacy, and quality are not verified through the agency's standard review process. As the shortage of brand-name semaglutide products has eased, the FDA has moved to restrict the continued compounding of the drug.

Alleged Consumer Harm: Paying a Premium for a Different Product

The lawsuit alleges that consumers suffered financial harm by paying prices comparable to — or marketed alongside — those of FDA-approved GLP-1 drugs, while allegedly receiving a product that lacked the same regulatory backing, clinical validation, and manufacturer quality controls.

According to the complaint, this constitutes deceptive and unfair business practices. The plaintiff seeks to represent a class of similarly situated consumers who purchased Hims & Hers compounded semaglutide products based on the company's alleged misrepresentations.

The case adds to a growing wave of legal scrutiny facing telehealth companies that rapidly expanded into the GLP-1 compounding market during the height of the semaglutide shortage.

Hims & Hers Has Not Yet Responded Publicly

As of publication, no public statement from Hims & Hers addressing the specific allegations in this lawsuit has been identified. The company has previously defended the quality and transparency of its compounded semaglutide offerings in response to broader industry criticism. InjuryClaims.com will update this article as the case develops.

A Broader Legal Landscape for GLP-1 Compounders

This lawsuit is not the first legal challenge to emerge from the compounded semaglutide market. Novo Nordisk, the manufacturer of Ozempic and Wegovy, has filed lawsuits against various compounding pharmacies and telehealth providers, alleging trademark infringement and consumer deception. Regulatory agencies have also raised concerns about how some companies have marketed compounded GLP-1 products.

The Hims & Hers class action reflects a parallel track of consumer-driven litigation, with patients — rather than drug manufacturers — seeking accountability for alleged misrepresentations made at the point of sale.

Related Cases

• Ozempic Lawsuit: Gastroparesis and Stomach Paralysis Claims
• GLP-1 Drug Litigation: What Patients Need to Know
• Compounded Drug Safety: FDA Warnings and Consumer Rights

Lawsuit: To be confirmed upon full complaint review

Case Number: Not yet confirmed

Court: Not yet confirmed

Plaintiffs' Attorney(s): Not yet confirmed

This article is for informational purposes only. Consult your doctor before making any changes to your medication or treatment plan.

Have you purchased compounded semaglutide products from Hims & Hers? Share your experience in the comments below.